Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
F1000Research|April 30, 2019
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceKelly Bailey, Carrye Cost, Ian Davis, et al.
Pediatric Blood & Cancer|March 26, 2014
A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group studyMaryam Fouladi, John P Perentesis, Christine L Phillips, et al.
Journal of the National Cancer Institute|October 19, 2014
Combining targeted agents with modern radiotherapy in soft tissue sarcomasPhilip Wong, Peter Houghton, David G Kirsch, et al.
Cancer Research|March 18, 2022
M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and ProgressionPooja Yadav, Panneerdoss Subbarayalu, Daisy Medina, et al.
Cancer Research|March 5, 2014
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancerKellie S Rath, Shan K Naidu, Pushpa Lata, et al.
International Journal of Cancer|December 20, 2018
Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcomaWenyue Sun, Bishwanath Chatterjee, Jack F Shern, et al.
Oncogene|February 10, 2021
MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcomaXin-Yu Ke, Ye Chen, Valarie Yu-Yan Tham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingMichele Dowless, Caitlin D Lowery, Terry Shackleford, et al.
Molecular Oncology|December 8, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinibUgne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera, et al.
Plos One|July 28, 2017
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcomaPeter Y Yu, Heather L Gardner, Ryan Roberts, et al.
Pageof 6